Level D· Scientific groundwork from lab and animal studiesAnimal StudyEurope PMCOpen access

Tissue Stem Cell-Based Therapies in Parkinson's Disease: A Scoping Review of Therapeutic Mechanisms and Translational Outcomes

Cueva E., Wiesheu A., Sordo Z., González J., Falconi S., Rodas JA.

Animal Study with a reported sample of 25 on Neuroinflammation, published in Cells (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Cells (2025)
Reported sample size
25
Source database
Europe PMC
PMID
40497998
PMCID
PMC12154328
DOI
10.3390/cells14110822
Citations
3

Abstract (original English)

(1) Background: Parkinson's disease (PD) is a progressive neurodegenerative disorder characterised by dopaminergic neuronal loss. Tissue stem cell-based therapies have emerged as promising candidates for disease modification and symptomatic relief. This scoping review aims to systematically synthesise the literature on tissue stem cell therapies for PD across cellular, animal, and human studies, with a focus on transplantation strategies, mechanisms of action, and therapeutic outcomes. (2) Methods: We identified 1017 records by querying PubMed, Scopus, Cochrane, and the Virtual Health Library. After screening and applying eligibility criteria, 33 experimental studies were included. Data were extracted on study design, tissue stem cell source, type of subject, and therapeutic effects. (3) Results: Most studies (n = 25) involved animal models, with a minority (n = 8) focusing on human applications. Tissue stem cell therapies showed potential to promote dopaminergic differentiation, reduce inflammation and apoptosis, and improve behavioural and motor outcomes. Autologous transplants yielded a higher safety and efficacy compared to allogeneic ones. The beneficial mechanisms of tissue stem cells included neurotrophic support, mitochondrial protection, modulation of the gut-brain axis, and α-synuclein clearance. (4) Conclusions: Tissue stem cell therapies represent a promising approa

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
Stem CellsAnimalsHumansParkinson DiseaseTreatment OutcomeStem Cell TransplantationDopaminergic NeuronsCell- and Tissue-Based TherapyTranslational Research, Biomedical

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research